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Abstract 
De-differentiated liposarcoma (DDLPS) is a malignant soft tissue sarcoma known for its 
metastatic potential and high rate of local recurrence. Surgical resection remains the standard 
treatment for DDLPS due to the limited efficacy of systemic chemotherapy and radiation [1]. 
Chemotherapy is limited by systemic effects that prevent accumulation at the tumor site, thereby 
requiring higher dosages leading to adverse side effects. We started the development of a 
targeted drug delivery system that is responsive to specific signals in the tumor and its 
microenvironment to treat locally recurrent DDLPS. DDLPS is marked by amplification in the 
chromosomal locus 12q13-15 which is associated with amplifications of the oncoprotein mouse 
double minute 2 (MDM2) [2]. Mdm2 is found to be upregulated in nearly all cases of DDLPS 
and is associated with increased local recurrence rates [3]. Given that Mdm2 can serve as a 
reliable diagnostic marker, we wanted to find a downstream product that could be used to prompt 
controlled drug delivery. Matrix metalloproteinases (MMPs) are a family of endoproteases that 
contribute towards the degradation of the extracellular matrix (ECM). MMPs have previously 
been used in targeted drug delivery systems and are upregulated by increased levels of MDM2 
[4]. Therefore, the relationship between MDM2 and MMPs demonstrated the potential to be 
exploited for a controlled drug delivery system. To make this system transferrable to a clinical 
setting, we began characterization of the MMPs being released from liposarcoma (LPS) cell 
lines. We used polymerase chain reaction (PCR) to gain a better understanding of how increased 
Mdm2 levels impacted MMP expression and found that MMP-1, -2, and -14 mRNA expression 
was significantly increased in cell lines with higher Mdm2 expression. Based on these results, we 
designed four peptide substrates that were amenable to degradation by the identified MMPs. 
Results indicated a trend in the QGIW and RSLS peptides that suggested preferential 
degradation by LPS cell lines with high levels of MDM2. To improve the design of these 
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crosslinkers we used fluorescent peptide zymography to measure which MMPs might be 
contributing to the degradation of each peptide. We found that MMP-1 and -2 are driving the 
degradation of the selected substrates by LPS cell lines. Future work will aim to improve the 
design of the peptide substrates to make them more selective for degradation by MMP-1 and -2 
specifically.  
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Introduction 
Motivation 
Liposarcoma (LPS) accounts for approximately 20% of all soft tissue sarcomas. LPS develops in 
any part of the body that contains adipocytes but is most typically found in the limbs or 
peritoneal cavity [5]. The most common subtypes of LPS are well-differentiated and de-
differentiated liposarcoma (DDLPS). Of these, DDLPS presents significant clinical challenges 
with only a 10% 10-year survival rate due to frequent local recurrence, metastatic potential and 
deep-seated, unresectable tumors [6]. 
 
Current methods for treating DDLPS including surgery, radiation therapy, and chemotherapy 
remain mostly unchanged since the 1970s. Multiple surgeries are often performed in order to 
address local recurrence, but with limited improvements in overall patient survival [1]. 
Doxorubicin, the primary chemotherapy used to treat DDLPS, is classified as anthracycline 
which means it is a type of chemotherapy that works by intercalating deoxyribonucleic acid 
(DNA) in cells in order to prevent cell growth and multiplication (Figure 1) [7]. Doxorubicin is 
delivered systemically, and relies on accumulation of drug at the tumor site for efficacy. By the 
enhanced permeability and retention (EPR) effect, the drug concentration should be highest in 
the tumor as a result of hypervascularization and lack of lymphatic draining capabilities (Figure 
2) [8]. However, when chemotherapy is given to a patient, it enters systemic circulation and is 
distributed to the tumor and other tissues based on mass and blood flow rate [9]. With a lack of 
active tumor targeting, the drug must be delivered in high dosages to have an effect, resulting in 
significant off-target effects, such as nausea, hair loss and weakening of the cardiac muscle [10]. 
Additionally, systemic therapies have short half-lives requiring multiple dosages. Moreover, 
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doxorubicin has an upper-bound of patient responsiveness at only 25% [11]. It is important to 
note that the ineffectiveness of chemotherapies such as doxorubicin in treating DDLPS tumors is 
not a result of the type of drug being administered. In vitro studies have shown that doxorubicin 
is effective at killing cells. In vivo data, however, shows that systemic therapies struggle to 
localize treatment to the tumor site. Moreover, drug dosage levels have to be reduced from an 
adequate concentration needed to treat DDLPS tumors in order to limit systemic toxicity. 
Because of the drawbacks of current treatments, there is a need for alternatives that can 
overcome present limitations by restricting delivery of the drug to the tumor site and controlling 
the release of the drug only when it is needed. A drug delivery system with controlled release 
properties that can be implanted at the site of the tumor would represent such a solution.  
 
Figure 1: Doxorubicin inhibits DNA synthesis by acting as an DNA intercalating agent [12]. 
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Figure 2: EPR effect results in more distribution of drug to tumor site due to enhanced 
vascularization and reduced lymphatic drainage [13]. 
 
To develop a drug delivery system for DDLPS, properties specific to DDLPS that could prompt 
the release of drugs needed to be identified. One characteristic of DDLPS is the presence of 
mouse double minute 2 (MDM2) in nearly 100% of cases. However, MDM2 cannot, itself, 
prompt release of the drug. MDM2 is not a protease and protease activity has been used 
extensively in targeted drug delivery systems. Therefore, we needed to identify a downstream 
regulator of MDM2 that could. DDLPS possesses amplifications in chromosomal locus 12q13-
15 which contains Mdm2, an oncogene [2]. Data gathered from in vitro experiments performed 
on Simpson-Golabi-Behmel syndrome (SGBS) pre-adipocytes (PAs) showed that MDM2 
released in extracellular vesicles (EVs) by DDLPS cell lines, can be transferred to healthy PAs, 
leading to an increase Mdm2 copy number and ultimately the activation of MMP-2 (Figure 3) 
[14]. MMPs contribute towards cancer cell migration and invasion, the initial stages of 
metastasis, by degrading the extracellular matrix (ECM), supporting angiogenesis, and regulating 
growth factor bioavailability and activity [15]. Given their proteolytic ability and the fact that 
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they are upregulated in DDLPS, harnessing the increased MMP activity provides a promising 
opportunity for a drug delivery system. 
  
 
Figure 3: Mdm2 from LPS cells is transferred to PAs through EVs. The resulting increase in 
Mdm2 expression in PAs results in increases in MMP-2 activity [14].  
 
Although several mediums have been explored for the application of controlled drug delivery, 
hydrogels are particularly appealing for their modular biological and mechanical characteristics, 
high water content, biocompatibility and low cytotoxicity. There are several ways to control the 
release of a drug from a hydrogel including mesh size manipulation, network degradation or 
mechanical deformation. Of these, network degradation through proteolysis of a peptide 
crosslinker with well-defined degradation represents the most controllable, with half-lives of 
weeks to months [16]. Given this, we aim to design a system that is responsive to the increased 
MDM2-dependent MMP activity.  
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The overall goal of this project is to measure the impact of elevated Mdm2 copy number on 
MMP activity in vitro and use the information to design an MMP-sensitive controlled drug 
delivery system. First, we measured the mRNA expression of MMPs typically upregulated in 
cancer to inform the design of a peptide crosslinker that is amenable to upregulated MMP 
activity in LPS. Then, we incorporated the selected peptide substrates into a hydrogel assay to 
measure global MMP activity and preferential degradation by LPS cell lines. Finally, in order to 
identify which MMPs were responsible for the degradation of the selected peptides, we 
performed substrate gel zymography. To confirm that the measured degradation was due to 
Mdm2-induced MMP activity, we also treated cells with an MDM2 inhibitor, SAR405838 
(SAR). Although we were only able to measure trends between Mdm2 amplification and peptide 
degradation, we believe that future work can build upon these results to design a more specific 
peptide substrate. This treatment method, when paired with surgery, has the potential to reduce 
damage to healthy tissue and local recurrence rates by primarily targeting tissues with cancerous 
behavior.  
 
 
Significance 
DDLPS is the most common form of LPS, associated with high local recurrence rates, making it 
difficult to treat. Radical surgery remains the primary method for treatment as radiation and 
chemotherapy have shown limited efficacy. There is a need for improved treatment protocols 
that can cater to its unique characteristics. Our approach involves defining the relationship 
between MMP activity and elevated Mdm2 copy numbers measured in nearly all DDLPS cells. 
With this knowledge, we hope to design a degradable biomaterial that locally delivers 
14 
 
chemotherapeutic drugs to the tumor site. This method could provide a safer and more effective 
way of treating LPS because it will not rely on accumulation of the drug at the tumor site by the 
EPR effect. The goal would be to implant the drug delivery hydrogel directly after surgical 
resection of the tumor, with the drug being released in response to recurrence and subsequent 
elevated MMP activity. The findings of this project can also impact the development of better 
treatment protocols for other locally recurrent diseases such as glioblastoma. 
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Background  
MDM2 
Cancer development can be attributed to a variety of different factors. However, many types of 
cancer possess a defective p53 pathway. p53 is a protein whose primary function is to suppress 
the formation of tumors by repairing defective DNA, arresting cell growth and signaling 
apoptosis. It is estimated that approximately 50% of all human cancers have some form of p53 
mutation [17]. The causes of reduced p53 functionality vary, yet one mechanism is prominent: 
the negative regulatory feedback loop between p53 and MDM2. Many types of cancers including 
LPS possess overamplification of Mdm2. As an oncoprotein, it is known to target tumor 
suppressors such as p53. The primary functions of p53 such as regulating the cell cycle and 
triggering apoptosis, are disrupted by the binding of MDM2. Acting as an E3 ubiquitin ligase, 
MDM2 monomerically ubiquitinates p53, marking it to be degraded by proteasomes (Figure 4) 
[18]. MDM2 is upregulated in nearly 100% of DDLPS cases [19]. It has therefore been used as a 
reliable diagnostic marker of LPS and has been labeled as an oncogene that promotes tumor 
formation. 
 
 
 
 
 
 
 
Figure 4: MDM2 marks p53 for degradation by the proteasome. DDLPS is marked by 
overamplification of the oncogene, Mdm2. MDM2 binds to the cell-cycle regulator p53 and 
marks it for degradation in the proteasome. Degradation of p53 leads to tumor progression [20]. 
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MMPs 
MMPs are a family of zinc-dependent endopeptidases that have been identified as critical 
regulators of cancer progression. The primary function of MMPs involves the degradation and 
remodeling of the ECM. There are currently over 20 identified MMPs in the human body and 
they have a role in cleaving a variety of substrates such as chemokine, growth factors, cell-
binding proteins, and collagen [21]. MMPs are initially translated as inactive, pro-MMPs. Upon 
activation they become proteolytically active and contribute to cellular invasion by cleaving 
stromal macromolecules. This is important because by allowing cells to invade, they can drive 
primary tumor growth, local recurrence and metastasis. When studying MMPs, expression levels 
can be measured using polymerase chain reaction (PCR) which accounts for MMPs at the 
transcriptional level or western blot analysis which accounts for MMPs at the protein level. 
Activity levels, on the other hand, are measured using peptide zymography. It is critical to study 
MMPs on both levels because expression levels do not have a direct correlation with activity 
levels. Clinically, researchers have established a positive correlation between upregulation in 
MMP activity and a poor patient prognosis. For example, in a study of patients with human 
breast cancer, a high expression of MMP-2 and MMP-9 was found in 83.75% of tissue samples. 
They concluded there was a closely linked relationship between lymph node metastasis and 
tumor staging [15]. MMP-targeting inhibitors have been tested clinically but have not been 
highly successful, likely due to compensation strategies and off-target effects. Gaining a better 
understanding of how these enzymes are regulated in cancer is critical. It can lead to the 
development of more efficacious treatment strategies that use MMPs as an asset (such as the 
controlled drug delivery system we are designing) rather than a target. 
 
17 
 
SAR 
SAR is a small molecule that inhibits the interaction between MDM2 and p53. Inhibition of the 
interaction between MDM2 and p53 occurs when SAR binds to MDM2 and is correlated with 
decreased MMP activity [14]. SAR binds to MDM2 with a K(i) = 0.88 nmol/L, demonstrating a 
high affinity that is greater than 10, 50, and 1000 times more potent than other MDM2 inhibitors: 
MI-219, nutlin-3a, and the p53 peptide, respectively. Uniquely, SAR possesses the same 
important p53 amino acid residues that MDM2 binds to with high specificity. This specificity is 
bolstered by supplemental interactions of SAR with the N-terminal region (region that binds to 
p53) of MDM2. Studies have shown that SAR also has the ability to activate wild-type p53. 
Results showed tumor regression and growth inhibition in mouse xenograft models of SJSA-1 
osteosarcoma, RS4;11 acute leukemia, LNCaP prostate cancer, and HCT-116 colon cancer [22]. 
This makes SAR an ideal candidate for comparing the effects of decreased MDM2 interaction 
with p53 on MMP activation and preferential degradation of a peptide substrate within LPS cell 
lines. We hypothesized that by disrupting the interaction between MDM2 and p53 using SAR, 
MMP activity would decrease.  
 
Figure 5: Co-crystal Structure of SAR405838/MDM2 at 2.1 Å resolution (right)  
Superposition of SAR405838/MDM2 and p53 peptide/MDM2 co-crystal structure (left) [22]. 
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Controlled Drug Delivery 
Controlled drug delivery systems are a technology that have been developed over the past 60 
years. The first generation (1950-1980) concentrated on the development of oral and transdermal 
controlled release formulations. The second generation (1980-2010) concentrated on the 
development of zero-order release systems, self-regulated drug delivery systems, long-term 
depot formulations, and nanotechnology-based delivery systems. Now, in the third generation the 
focus is on overcoming the limitations of previous generations and advancing the compatibility 
of these systems in clinical applications and in vivo [23]. Given the current focus, the purpose of 
controlled drug delivery systems has been established as maximizing the efficacy of therapeutic 
drugs while minimizing the adverse effects by releasing only the necessary dose at the 
appropriate time. This technology is needed to advance current treatment methods with 
numerous side effects and minimal success in cancers such as DDLPS. Examples of current drug 
delivery systems include carbon nanotubes (CNTs), micelles and hydrogels. CNTs are artificial 
one-dimensional nanomaterials that are composed of carbon and sheets of graphene rings that 
were rolled to create the hollowed-out nanotube shape seen in Figure 6. When loaded with 
doxorubicin, CNTs are very effective at treating multidrug resistance in leukemia cells. They 
have not yet been shown to be an effective treatment for soft tissue sarcomas such as DDLPS. 
Micelles are spherical nanomaterials that are composed of amphipathic molecules that 
spontaneously form a hydrophobic interior and hydrophilic exterior in aqueous solutions (Figure 
6). Micelles are useful for reducing systemic toxicity and improving delivery of drug to the 
original tumor site in breast, lung and ovarian cancers [24]. One of the major drawbacks of 
micelles, however, is their instability, especially in the presence of environmental changes. They 
have a tendency to dissociate prior to reaching their destination [25]. Hydrogels are a three-
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dimensional network of hydrophilic polymer chains held together by crosslinkers. They are very 
versatile in terms of their applications such as forming material for artificial organs and contact 
lenses, biosensors and drug delivery vehicles. Hydrogels are advantageous because of their 
biocompatibility, minimal cytotoxicity, high biomacromolecule encapsulation efficiency and 
ability for drug delivery systems to be administered in various forms (i.e. oral, rectal, ocular, 
epidermal, and subcutaneous). Hydrogels also offer multiple mechanisms for controlled drug 
release such as mesh size manipulation, network degradation or mechanical deformation. For 
these reasons and the sensitivity to MMP degradation, we chose hydrogels as our form of drug 
delivery system. 
  
 
Figure 6: Drug delivery system nanocarriers. Drugs are conjugated to the selected nanomaterials 
and are distributed in a targeted and controlled manner to the tumor site [24]. 
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MMPs in Controlled Drug Delivery Systems 
Given the strong positive correlation with MDM2, MMPs demonstrated the potential to be 
incorporated in our controlled drug delivery system. Also, MMPs have been used previously in 
targeted drug delivery systems. As stated in my section on MMPs, upregulation in MMP activity 
is associated with cancer. This has established MMPs as predictable cancer biomarkers. 
Therefore, when MMP activity has been tailored to targeted drug delivery systems, they have 
been described as a strong and stable stimulus for specific tumor targeting [26]. In fact, studies 
have shown MMPs can help prompt cellular endocytosis and heightened penetration into deep-
seated tumors [27]. Figures 7 and 8 show some examples of the plethora of modalities that 
MMPs are used in for targeted drug delivery. The essential mechanism remains the same 
whereby an MMP degradable substrate is incorporated into the drug nanocarrier. The 
upregulated MMP activity that cancer cells yield would result in increased degradation of this 
substrate and the drug would then be released into the tumor microenvironment. For our system 
in particular, MMP degradable peptide substrates used as crosslinkers are conjugated into 
hydrogels. MMPs then degrade these cross linkers in order to release the drug. 
 
 
 
 
 
 
 
Figure 7: MMPs used as triggers for targeted drug delivery systems. Drugs are conjugated to 
nanocarriers with MMP degradable substrate. MMPs degrade substrate and prompt release of 
drug [28]. 
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Figure 8: MMPs act as reducing agent in hydrogel-based controlled drug delivery systems. Drugs 
are conjugated to hydrogel with MMP degradable peptide substrate. MMPs degrade substrate 
and prompt release of drug [29]. 
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Materials and Methods 
Cell Culture 
Lisa-2, Lipo863, and Lipo246 LPS cell lines were provided by the Pollock Lab. Lisa-2, Lipo863, 
and Lipo246 presented with low, medium and high Mdm2 amplification, respectively [30]. They 
were cultured in Dulbecco’s Modified Eagle Medium (DMEM) media. The media contained 
10% fetal bovine serum (FBS), 1% penicillin-streptomycin, and 1% L-glutamine. The cells were 
maintained in a humidified incubator at 37ºC and 5% CO2. 
 
 
Peptide Synthesis 
Peptides GGPQG↓IWGQKDde(Adoo)C (abbreviated as QGIW throughout the text and figures to 
denote the P2-P2’ residues; ↓ indicates cleavage site); 
GPLA↓C(MeOBzl)WARKDdeDDK(Adoo)C (abbreviated as LACW throughout the text and 
figures to denote the P2-P2’ residues; ↓ indicates cleavage site); KMttGPRS↓LSGKDde(Adoo)C 
(abbreviated as RSLS throughout the text and figures to denote P2-P2’ residues; ↓ indicates 
cleavage site); GPL↓GL(Dap)DdeAR(Adoo)C (abbreviated as PLGL throughout the text and 
figures to denote P2-P2’ residues; ↓ indicates cleavage site) were synthesized using Fmoc solid 
phase peptide synthesis (CEM Liberty Blue Peptide Synthesizer, Matthews, NC) using a Rink 
Amide MBHA resin (EMD-Millipore, Burlington, MA). The QGIW peptide is a commonly 
used, collagen I-derived sequence [31]. LACW is an artificial, commercially available peptide 
that has been optimized for MMP-14 detection [32]. RSLS was designed and implemented for 
the detection of MMP-2 and MMP-9 [33]. PLGL is a commonly used, broad-spectrum MMP-
sensing peptide that has been characterized for the detection of MMP-1, -2, -7, -8, -9, -12, -13, -
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14, -15, -16 [34]. All Fmoc protected amino acids and Fmoc-8-amino-3,6-dioxaoctanoic acid 
(Adoo) were purchased from Chem-Impex (Chem-Impex, Wood Dale, IL).  
 
Peptides were functionalized with a quencher (dabcyl) and fluorophore (fluorescein) [35]. 
Briefly, a dabcyl succinimidyl ester (Anaspec, Fremont, CA) was coupled to the amino terminus 
of the peptide in dimethyl formimide (DMF) with 6 eq. N,N’-diisopropylethylamine (DIPEA) 
and reacted overnight. For the RSLS peptide, the dabcyl succinimidyl ester was coupled to the 
side-chain amine in the N-terminal KMtt. KMtt was deprotected using 9 washes of 1.8% TFA in 
DCM for three minutes each. An orthogonally protected lysine (KDde) or diaminopropoinoic acid 
(DapDde) was then deprotected twice in 2% hydrazine monohydrate in DMF for 10 min and a 
fluorescein NHS ester (Anaspec) was coupled to the resultant free amine in the same manner as 
dabcyl. The peptides were cleaved from the resin beads by incubating in a cleavage cocktail of 
trifluoroacetic acid, phenol, triisopropylsilane and water (95/2.5/1.25/1.25 v/v) for 3 h at room 
temperature, and precipitated in chilled diethyl ether 3 times. Peptides were purified by reverse 
phase high performance liquid chromatography (RP-HPLC; Hitachi, Schaumburg, IL) (QGIW: 
30-70%; LACW: 52-70%; RSLS: 30-70%; PLGL: 10-70% gradient of acetonitrile at 2% 
ACN/min) and molecular weight (QGIW: 1884 Da; LACW: 2336 Da; RSLS:1743 Da; 
PLGL:1481 Da) was verified by matrix-assisted laser desorption ionization time-of-flight mass 
spectrometry (MALDI-TOF; Bruker, Billerica, MA). 
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Real Time-Polymerase Chain Reaction 
Cells were plated at 30,000 cells/cm2 and cultured for 24 h in complete growth medium. RNA 
was isolated using the RNeasy RNA isolation kit (Qiagen) according to the manufacturer’s 
protocol. 2 ng of mRNA was then reverse transcribed using the iScript reverse transcription kit 
(Bio-rad), and used for qRT-PCR. Primers were obtained from the Harvard Primer Bank 
(https://pga.mgh.harvard.edu/primerbank/) and verified using Primer BLAST 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/). qRT-PCR was run using SYBR Green 
(Thermo Fisher Scientific) for detection. Primers were used at 900 nM, and expression levels 
were normalized to the endogenous control, 18S (Thermo Fisher Scientific). Primer sequences 
were as follows: 
MMP-1 F: AAGATGAAAGGTGGACCAACAATT 
R: CCAAGAGAATGGCCGAGTTC 
MMP-2 F: AACTACGATGACGACCGCAAGT 
R: AGGTGTAAATGGGTGCCATCA 
MMP-13 F: CATGAGTTCGGCCACTCCTT  
R: CCTCGGAGACTGGTAATGGC 
MMP-14 F: AAGGCCAATGTTCGAAGGAA  
R: GGCCTCGTATGTGGCATACTC 
Table 1: Primer Sequences 
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Hydrogel Encapsulation 
Hydrogel composition consisted of 10 wt% 8-arm 40K Poly(ethylene glycol) norbornene (PEG-
NB), 12.75 mM MMP-degradable crosslinker (0.7 thiol:ene), 0.5 M NaOH, 1 mM RGD pendant 
peptide, 2 mM Lithium phenyl-2,4,6-trimethylbenzoylphosphinate (LAP), and 0.25 mM MMP 
peptide. The MMP-degradable crosslinker is flanked by thiol moieties that are able to conjugate 
with the norbornene groups in the PEG. RGD is a cell adhesion peptide sequence for cells to 
adhere to it. LAP is a photoinitiator that catalyzes the thiol-ene reaction in the presence of 
ultraviolet (UV) light (365 nm). Various MMP degradable peptides were used including RSLS, 
PLGL, QGIW, and LACW in order to identify which substrate would be best suited for 
preferential degradation by MMPs upregulated by Mdm2 overamplification. A concentrated 
solution of cells and phosphate buffered saline (PBS) were added to the hydrogel mixture. 
Triplicates of each condition were transferred to a black, round-bottom 96-well plate. Plate was 
placed under UV light (4 mW/cm2; 365 nm) for 3 minutes. 150 μL of DMEM media +/- SAR 
treatment at a concentration of 0.3 μM was the added to the respective wells. Cells were 
transferred to an incubator at 37ºC and 5% CO2. After 18 h, 15 μL of AlamarBlue at a 
concentration of 10% was added to each well. At 24 h, fluorescence readings were captured 
using a SpectraMax M5 plate reader at 494 nm excitation/521 nm emission wavelength for 
peptide degradation and 560 nm excitation/590 nm emission for alamarBlue. Averages of each 3 
x 3 well scan were calculated for the detection of overall peptide degradation. 
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Figure 9: Schematic of the PEG hydrogel platform functionalized with the fluorescent peptide 
biosensor. Degradation of the biosensor by cell-secreted MMPs results in separation of the 
quencher and fluorophore resulting in an increase in fluorescence intensity. 
 
 
Peptide Zymography 
For zymographic analyses, cells were seeded at a density of 30,000 cells/cm2 in duplicate wells 
of a 6-well plate for 24 h in 10% FBS media, washed with PBS twice and then cultured in serum-
free media for an additional 24 h. Media samples were collected and concentrated using 10-kDa 
Amicon Ultra Centrifugal Filter Units (EMD-Millipore). Conditioned cell media samples were 
loaded under non-reducing conditions onto prepared fluorescent peptide zymography gels. 
Fluorescent peptide zymography gels were prepared as previously described [36]. The samples 
were electrophoresed at 120 V at 4ºC for 1.5 h. Following electrophoresis, gels were washed 
three times for 15 min each at room temperature under gentle agitation in renaturing buffer 
containing 2.5% Triton X-100 in 50 mM Tris-HCl, pH 7.5. Gels were then transferred to a 
developing buffer solution, 1 µM ZnCl2 and 5 mM CaCl2 in 50 mM Tris-HCl, pH 7.5, overnight 
at 37ºC under gentle agitation. Fluorescent images of the fluorescent peptide gels were captured 
at 24 h using a GE Amersham Typhoon 9410 Gel Imager (Excitation 488/Emission 521).  
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Figure 10: Schematic of fluorescent peptide zymography. Fluorescent peptides incorporated into 
polyacrylamide gels using a crosslinker. Gels are electrophoresed and degradation can be 
visualized and quantified based on change in fluorescent intensity [36]. 
 
 
Statistical Analysis 
For qt-PCR, data analysis was performed by two-way ANOVA followed by Dunnett’s multiple 
comparisons test using the Lisa-2 cell line as the control. 
 
For hydrogel encapsulation data analysis, triplicate wells were averaged and the background 
values of gels with no cells were subtracted from cell-containing gels for each of the four 
peptides screened. To identify a peptide that is preferentially degraded by LPS cells with 
overamplification of Mdm2, RFU values of LPS cell lines at 24 h were normalized to Lisa-2 
cells. Analysis was performed by one-way ANOVA with Dunnett’s multiple comparisons test 
using the Lisa-2 cell line as the control. 
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For peptide zymography data analysis, a one-way ANOVA followed by Tukey’s multiple 
comparisons test was performed. Graphs were created and statistical analysis was performed 
using GraphPad Prism 7.0 software (GraphPad Sofware, Inc, San Diego, CA). At least three 
independent experiments were carried out for each experiment and data are shown as meanSD 
(n=3), unless otherwise noted. 
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Results and Discussion 
Controlled Drug Delivery System Peptide Screen 
The purpose of the PCR experiments was to investigate MMP mRNA expression. We wanted to 
understand how the suppression of MDM2 would change MMP expression levels. This would 
give us an idea of the specific MMPs we could target for the development of a controlled drug 
delivery system. Lisa-2 cells have no amplification of Mdm2. Lipo863 and Lipo246 cell lines 
have low and high levels of Mdm2 amplification, respectively. The MMPs selected for PCR 
experimentation were chosen based on their history of being upregulated in cancer and the desire 
to have a range of MMP types. MMP-1 and MMP-13 are collagenases, MMP-2 is a gelatinase 
and MMP-14 is membrane-bound and a primary degrader of collagen.
 
Figure 11: MMP-1, -2, -13, -14 mRNA expression in LPS cell lines. VC: vehicle control 
(DMSO). Results are represented as n=4, meanSD. *p<0.05, **p<0.01, ***p<0.005. 
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MMP-1 expression was upregulated approximately 80-fold in Lipo863 cells compared to Lisa-2 
cells (Figure 11). Treatment of Lipo863 cell lines with the MDM2 inhibitor, SAR, resulted in a 
decrease in MMP-1 expression by 50% (approximately 40-fold higher compared to Lisa-2). 
MMP-2 expression was upregulated in the Lipo863 (5-fold) and Lipo246 (7-fold) cell lines. SAR 
treatment decreased MMP-2 expression by ~25% in both cell lines. A similar trend was 
measured in MMP-14. Interestingly, SAR treatment of Lisa-2 cell lines appeared to moderately 
increase MMP expression in all cases. This is likely due to the fact that Lisa-2 cell lines do not 
exhibit any amplification of Mdm2. Previous work has shown that treatment of Lisa-2 cell lines 
with SAR, while increasing p53 expression levels, also has a positive regulatory feedback effect 
that results in increased Mdm2 expression [37]. This may in turn have a downstream effect that 
increases MMP expression, and ultimately activity. Lipo863 and Lipo246 cells, on the other 
hand, have increased copy numbers and overamplification of Mdm2. Normally, these cells have 
little or no functioning p53 protein. P53 has been previously identified as a negative 
transcriptional regulator of MMP expression [37]. Therefore, increased p53 expression from 
SAR treatment can lead to decreased MMP transcription. This indicates two potential effects of 
SAR treatment on MMP expression. The responses toward the SAR treatment are dependent on 
whether cells have normal p53 and Mdm2 levels or low p53 and high Mdm2 levels. There is a 
trend showing increased upregulation of various MMP expression levels with increased Mdm2 
amplification. This demonstrated an association between MMP expression and Mdm2 
amplification in DDLPS. This is indicative of a potential need to develop different controlled 
drug delivery systems targeting different MMPs to cater to the varying expression levels of 
different cell lines. 
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Assessment of Peptide Degradation 
The purpose of the hydrogel encapsulation experiments was to study MMP peptide degradation. 
We wanted to determine if there was a specific peptide that was preferentially degraded by 
MMPs secreted by DDLPS cancer cell lines with amplification of Mdm2 compared to those with 
no or low amplification of Mdm2. The peptides selected were chosen based on preferential 
degradation by the MMPs studied in the PCR experiments. PLGL serves as a general MMP 
sensor peptide. LACW is preferentially degraded by MMP-14 [38]. QGIW is preferentially 
degraded by the collagenases such as MMP-1, MMP-8, and MMP-13 [39]. RSLS is 
preferentially degraded by the gelatinases, MMP-2 and MMP-9 [40]. 
   
Figure 12: PLGL Peptide Degradation   Figure 13: LACW Peptide Degradation 
Results are represented as n=4, meanSD.   Results are represented as n=4, meanSD. 
VC: vehicle control (DMSO).    VC: vehicle control (DMSO). 
Lis
a-2
Lip
o8
63
Lip
o2
46
0
1
2
3
4
5
PLGL
VC + SAR (0.3 uM)
Lis
a-2
Lip
o8
63
Lip
o2
46
32 
 
 
Figure 14: QGIW Peptide Degradation  Figure 15: RSLS Peptide Degradation 
Results are represented as n=4, meanSD.  Results are represented as n=4, meanSD. 
VC: vehicle control (DMSO).    VC: vehicle control (DMSO). 
 
We want a peptide substrate whose degradation increases from Lisa-2 to Lipo863 to Lipo246 
with Mdm2 levels. Figure 12 shows that the PLGL peptide does not display a trend in increased 
degradation with Mdm2 overamplification. These results indicate PLGL is not an ideal candidate 
for our controlled drug delivery system. Additionally, the SAR treatment was used to investigate 
whether peptide degradation was the result of MDM2-induced MMP activity. We hypothesized 
that SAR treatment would inhibit MDM2 and ultimately decrease MMP activity. This was only 
the case for the Lisa-2 cells. The cell lines that should have been the most impacted by SAR 
inhibition, Lipo863 or Lipo246, slightly increased degradation after treatment. 
 
Figure 13 shows that the LACW peptide does not display a trend in increased degradation with 
increased Mdm2 overamplification status. These results indicate LACW is not an ideal candidate 
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for our controlled drug delivery system. Figure 13 demonstrates a trend with increasing peptide 
degradation from Lipo863 to Lisa-2 to Lipo246 cells. Upon SAR treatment, peptide degradation 
increased for Lisa-2 cells and decreased for Lipo863 and Lipo246 cells. This follows a similar 
trend seen in the PCR results. Although the degradation of the LACW peptide may be controlled 
by MMP secreted LPS cell lines, it does not appear to be correlated with Mdm2 levels. 
 
Figure 14 shows that the QGIW peptide does display a trend in increased degradation with 
increased Mdm2 amplification. Lisa-2 cells, those with no Mdm2 amplification had the lowest 
peptide degradation. Though the expectation was that the highest peptide degradation would be 
by the cell line with the highest Mdm2 amplification (Lipo246), this was not the case. The 
Lipo863 cells exhibited a much higher level of peptide degradation. Though this does not follow 
the exact degradation trend we expected, with adjustments to the peptide sequence, the peptide 
could become more favorable to Lipo246 peptide degradation. Upon SAR treatment, peptide 
degradation increased for Lisa-2 cells and decreased for Lipo863 and Lipo246 cells, as expected 
based on the PCR data.  
 
Figure 15 shows that the RSLS peptide does display a trend in increased degradation with 
increased Mdm2 amplification status. It follows the trend we expected to see where the cells with 
no overamplification of Mdm2, Lisa-2, have the lowest peptide degradation and the cells with the 
highest overamplification of Mdm2, Lipo246 have the highest peptide degradation. These results 
showing evident preferential degradation with Mdm2 amplification status indicate RSLS as the 
optimal peptide substrate to be incorporated into the controlled drug delivery system. However, 
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the differences in degradation between the cell lines were not statistically significant. SAR 
treatment increased peptide degradation by Lisa-2 cells and decreased peptide degradation by 
Lipo863 and Lipo246 cells, as seen previously.  
 
The peptide degradation results correspond with the results seen in the PCR experiments. They 
exhibit a trend showing that the impact of SAR treatment is based on p53 and Mdm2 status 
within cells. In cell lines with no overamplification of Mdm2, such as the Lisa-2 cells, SAR 
treatment has been shown to not have an effect on p53 levels [37]. The SAR treatment has been 
shown, however, to have an effect on MDM2 whereby levels are increased in cell lines with no 
overamplification [37]. Therefore, a potential downstream effect of increased MDM2 expression 
could be an increase in MMP expression. The increase in MMP expression levels with SAR 
treatment seen in the Lisa-2 cells in the PCR experiments likely prompted an increase in MMP 
proteolytic activity and ultimately increased peptide degradation. The decreased MMP 
expression levels with SAR treatment seen in the Lipo863 and Lipo246 cells resulted in the 
opposite outcome: decreased MMP proteolytic activity and ultimately decreased peptide 
degradation. Although the peptide screen did not reveal a definitive difference in peptide 
degradation with increased MDM2 expression (or a statistically significant decrease upon SAR 
treatment), the QGIW and RSLS peptide do appear to show a trend in that direction. By 
understanding the secreted MMPs that are likely driving the degradation of these peptide 
substrates, we can further improve the selectivity of the drug delivery platform. 
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Evaluation of Proteolytic Activity Causing Peptide Degradation 
The purpose of the peptide zymography experiments was to investigate what specific MMPs 
were contributing to the degradation of the various peptides. Determining which MMPs are 
actually cleaving the peptides can help indicate how the peptide designs can be refined for 
improved preferential degradation in future peptide substrates. 
 
 
 
     
Figure 16: Fluorescent peptide zymography         Figure 17: Fluorescent peptide zymography 
of the PLGL peptide.            of the LACW peptide. 
 
 
 
 
 
      
Figure 18: Fluorescent peptide zymography         Figure 19: Fluorescent peptide zymography 
of the QGIW peptide.                    of the RSLS peptide. 
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Figure 20: Fluorescent peptide zymography quantification. Conditioned media from Lisa-2, 
Lipo863, and Lipo246 cell lines was collected after culturing in serum free media +/- SAR (0.3 
μM) for 24 h. The conditioned media samples were electrophoresed in peptide zymography gels 
containing the QGIW, LACW, RSLS, and PLGL fluorescent peptide substrates. Results are 
represented as n=3, mean±SD. *p<0.05, **p<0.01, ***p<0.005. 
 
 
Figure 16 of the PLGL peptide shows cleavage by active MMP-1 (molecular weight = 54 kDa) 
by Lipo863 with and without SAR. Upon SAR treatment, MMP activity levels decreased as 
shown by the decrease in fluorescence intensity by 41% (p<0.05) in Figure 20. Despite the fact 
that a significant difference in activity was observed, it was only in the Lipo863 cell line. 
Additionally, net degradation of the PLGL peptide by each cell line revealed no increase in 
degradation by cell lines with higher levels of Mdm2.  
 
Figure 17 of the LACW peptide shows cleavage by active MMP-1 by Lisa-2 and Lipo863 cells 
with and without SAR. It also shows cleavage by pro MMP-2 (molecular weight = 72 kDa) by 
Lisa-2, Lipo863, and Lipo246 cells without SAR and Lipo246 cells with SAR. Finally, it shows 
cleavage by active MMP-2 (molecular weight = 62 kDa) by Lipo246 cells without SAR 
treatment. Upon SAR treatment, MMP-1 activity levels in the Lisa-2 cells decreased as shown by 
the decrease in fluorescence intensity by 40% in Figure 20. Upon SAR treatment, MMP-1 
activity levels in the Lipo863 cells decreased as shown by the decrease in fluorescence intensity 
by 57% in Figure 20. Upon SAR treatment, pro MMP-2 levels in the Lisa-2 and Lipo863 cells 
were undetectable. Upon SAR treatment, pro MMP-2 levels in the Lipo246 cells increased as 
shown by the increase in fluorescence intensity by 15% in Figure 20. For active MMP-1, 
Lipo863 cells exhibited more activity than Lisa-2 cells. For pro MMP-2, Lipo863 cells exhibited 
the most MMP activity while Lipo246 cells exhibited the least, however, Lipo246 cells were the 
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only ones to display active MMP-2. The LACW shows a consistent decrease in MMP activity 
with inhibition of MDM2 by SAR. However, it is not an ideal candidate for a peptide substrate 
for our controlled drug delivery system because it did not show preferential degradation at higher 
levels of MDM2 amplification in hydrogel encapsulation experiments which measure net 
proteolytic activity. 
 
Figure 18 of the QGIW peptide shows cleavage by active MMP-1 by Lisa-2, Lipo863, and 
Lipo246 cell lines without SAR, and Lisa-2 and Lipo863 with SAR. It shows cleavage by pro 
MMP-2 by all cell lines with and without SAR. It shows cleavage by active MMP-2 by Lipo863 
and Lipo246 with and without SAR. Finally, it shows cleavage by pro MMP-9 (molecular weight 
= 92 kDa) by all cell lines with and without SAR. Upon SAR treatment, active MMP-1 activity 
decreased for Lisa-2 cells by 72%, for Lipo863 cells by 60% (p<0.05), and for Lipo246 cells by 
100% as shown by the decrease in fluorescence intensity in Figure 20. Upon SAR treatment, pro 
MMP-2 activity decreased for Lipo246 cells by 48% and increased by 4% for Lisa-2 cells and by 
43% for Lipo863 cells as shown in Figure 20. Upon SAR treatment, active MMP-2 activity 
decreased for Lipo246 cells by 86% and increased by 31% for Lipo863 cells. Upon SAR 
treatment, pro MMP-9 activity increased for Lisa-2 cells by 96%, for Lipo863 cells by 21%, and 
for Lipo246 cells by 59% as shown by the increase in fluorescence intensity in Figure 20. The 
increased expression levels of MMP-1 by Lipo863 cells seen in the PCR experiments correspond 
to evident active MMP-1 activity seen in the zymography gels and the increased degradation of 
the QGIW peptide seen in the hydrogel encapsulations. Based on the zymographic analysis of 
the QGIW peptide, MMP-1 and MMP-2 are the primary MMPs secreted by LPS cells that are 
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responsible for its degradation. The selectivity of this peptide could be improved by making it 
more specific to these two MMPs. 
 
Figure 19 of the RSLS peptide shows cleavage by active MMP-1 by Lipo863 with and without 
SAR. It also shows cleavage by active MMP-2 by Lisa-2, Lipo863, and Lipo246 without SAR 
treatment, and Lipo246 with SAR treatment. Finally, it shows cleavage by pro MMP-9 by Lisa-
2, Lipo863, and Lipo246 without SAR treatment and Lisa-2 and Lipo246 with SAR treatment. 
Upon SAR treatment, active MMP-1 activity decreased for Lipo863 cells by 38% as shown by 
the decrease in fluorescence intensity in Figure 20. Upon SAR treatment, active MMP-2 activity 
decreased for Lisa-2 cells by 100%, for Lipo863 cells by 100%, and for Lipo246 cells by 36% as 
shown by the decrease in fluorescence intensity in Figure 20. Upon SAR treatment, pro MMP-9 
activity decreased for Lipo863 cells by 100% and increased by 47% for Lisa-2 cells and by 46% 
for Lipo246 cells as shown by Figure 20. 
 
Minimal MMP activity in PLGL and LACW zymography gels correspond to minimal peptide 
degradation seen in the hydrogel encapsulations. Higher levels of MMP activity in QGIW and 
RSLS indicate potential peptide sequences for incorporation into controlled drug delivery 
system.  
 
It is important to note the limitations of peptide zymography experiments. The technique is used 
to determine which MMPs might be contributing to peptide degradation. However, 
electrophoresis results in separation of the MMP-TIMP complexes and sometimes results in 
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incomplete re-folding of the enzymes. Therefore, MMPs which may otherwise be inactive appear 
active and vice versa. Therefore, the peptide zymography needs to be coupled with hydrogel 
encapsulation, which is a better measure of net proteolytic activity. Based on these results, 
QGIW and RSLS are the leading candidates for an MMP-sensitive drug delivery system 
targeting LPS cell lines with elevated Mdm2. Future work will focus on improving the selectivity 
of these peptides towards degradation by the specific MMPs secreted by LPS cells (MMP-1 and 
-2). 
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Conclusion and Future Direction 
DDLPS is a unique type of cancer that is highly, locally recurrent with a poor patient prognosis. 
DDLPS intervention strategies are a critical area of research due to the need to gain a better 
understanding of disease progression and for the development of new, effective treatment 
modalities. In this study, we investigated how to create a targeted drug delivery system to treat 
DDLPS based on preferential degradation of a drug-containing substrate by cells with high 
expression levels of Mdm2.  
 
In the results for the PCR experiments, we observed a trend where the cell lines with 
overamplification of Mdm2 (Lipo863 and Lipo246), showed significant increases in expression 
of MMP-1, MMP-2, and MMP-14 compared to the cell line with no overamplification of Mdm2, 
Lisa-2. When treated with MDM2 inhibitor, SAR, evident decreases in MMP expression was 
observed in both Lipo863 and Lipo246 cell lines. Lisa-2 cells, on the contrary, showed a general 
increase in MMP expression upon SAR treatment, likely due to the fact that they otherwise 
display no amplification of Mdm2.  
 
Based on the results of the qRT-PCR, we designed peptide substrates that were preferentially 
degraded by these MMPs. We observed a trend of preferential degradation according to Mdm2 
overamplification status in both the QGIW and RSLS peptide substrates. Despite the fact that the 
differences in peptide degradation were not significant, both peptides present viable options for 
substrates in an LPS-targeted drug delivery system.  
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Fluorescent peptide zymography was used to determine which MMPs were responsible for 
peptide degradation. We observed cleavage by active MMP-1, pro and active MMP-2, and pro 
MMP-9. MMP activity levels were highest in the QGIW and RSLS peptides, which aligned with 
the results of the hydrogel encapsulation experiments. Both peptides showed preference for 
degradation by MMP-1 and MMP-2. 
 
Future studies should focus on building upon our work by refining the peptide substrate to be 
incorporated into the targeted drug delivery system. QGIW and RSLS peptides are optimal 
candidates for this process and can be adjusted to further cater to the MMPs actively contributing 
to peptide degradation (MMP-1 and MMP-2). The next step would then involve actually 
designing the targeted drug delivery system and integrating the ideal, modified peptide substrate. 
Ultimately, the goal of this research is to improve therapeutic methods to treat and save patients 
suffering from DDLPS. 
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